RT Journal Article
SR Electronic
T1 Iron supplementation for patients undergoing cardiac surgery: a protocol for a systematic review and meta-analysis of randomized controlled trials
JF CMAJ Open
JO CMAJ
FD Canadian Medical Association
SP E623
OP E626
DO 10.9778/cmajo.20200204
VO 9
IS 2
A1 Matthew J. Cameron
A1 Latifa Al Kharusi
A1 Adam Gosselin
A1 Pouya Gholipour Baradari
A1 Anissa Chirico
A1 Alexandre Amar-Zifkin
A1 Stephen S. Yang
YR 2021
UL http://www.cmajopen.ca/content/9/2/E623.abstract
AB Background: Iron administration has been evaluated in several randomized controlled trials for the potential of increasing baseline hemoglobin values and decreasing the incidence of red blood cell transfusion during cardiac surgery. We describe the protocol for a study aiming to evaluate the efficacy and safety of perioperative iron administration in patients undergoing cardiac surgery.Methods: We will search MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and the Web of Science, from inception to Nov. 19, 2020, for randomized controlled trials in any language evaluating the perioperative administration of iron in adult patients undergoing cardiac surgery; we will also include the first 50 results from Google Scholar. The primary outcome will be the incidence of red blood cell transfusion from the study intervention time until 8 weeks postoperatively. The secondary outcomes will be the number of red blood cell units transfused; change in ferritin level, reticulocyte count and hemoglobin concentration after iron administration; and adverse events. We will assess the risk of bias with the Cochrane Collaboration Risk of Bias Tool, and will analyze the primary and secondary outcomes using a random-effects model.Interpretation: This study will summarize the current evidence about perioperative iron administration in patients undergoing cardiac surgery, help determine whether this intervention should be included in enhanced-recovery protocols, and shape future research if needed. The final manuscript will be submitted to a peer-reviewed journal. Trial registration: PROSPERO no. CRD42020161927